Faculty

Anna Wald

Professor, Epidemiology
Professor, Medicine - Allergy and Infectious Dis.
Professor, Laboratory Medicine and Pathology

206-520-4340

Education

MD Medicine, Mt Sinai School of Medicine, 1985
MPH Epidemiology, University of Washington, 1994
BA Comparative Religion, Wesleyan University, 1979

Contact

206-520-4340

University of Washington
Box 359928
325 9th Avenue
Seattle, WA 98104

Research Areas

Research Interests

Dr. Wald's current research centers on the epidemiology and natural history of chronic viral infections in immunocompetent and immunocompromised hosts. She is also working on clinical trials of antiviral therapeutics and prophylactic and therapeutic vaccines for viral pathogens. Other ongoing studies address the interaction between sexually transmitted infections and microbiome.

Recent Publications (PubMed)

Incidence and Management of Early Breakthrough HSV Infection Among Allogeneic Hematopoietic Stem Cell Transplant Recipients.
(2026 Aug 4)
medRxiv
Fischer MD, Mohan R, Wald A, Phipps AI, Ford ES, Gooley T, Tverdek F, Biernacki MA, McCulloch DJ, Boeckh MJ, Johnston C, Pergam SA
Herpes Simplex Virus Serostatus and 1-Year Mortality Among Allogeneic Hematopoietic Cell Transplant Recipients.
(2026 Aug 2)
medRxiv
Fischer MD, Johnston C, Boeckh MJ, Ford ES, Gooley T, Phipps AI, Winer RL, Biernacki MA, McCulloch DJ, Sandmaier BM, Greninger AL, Wald A, Pergam SA
Mathematical modeling of the population-level impact of hypothetical herpes simplex virus type 2 curative therapy.
(2026 May 25)
Commun Med (Lond) 6(1):
Ayoub HH, Jerome KR, Chemaitelly H, Wald A, Abu-Raddad LJ
The safety, reactogenicity, and immunogenicity of the self-amplifying mRNA COVID-19 vaccine GRT-R910 as a booster in healthy adults.
(2026 Apr 2)
Vaccine 77(): 128358
Whitaker JA, Rebolledo PA, Abate G, Babu TM, Rouphael NG, Wald A, El Sahly HM, Jooss K, Hart MG, Makowski M, Mu J, Carmack A, Archer JI, Roberts PC, Makhene M, Posavad CM, McElrath MJ, De Rosa SC, Coler R, Montefiori D, Eaton A, Suthar MS, Atmar RL, Hoft DF, DMID 20-0034 Study Team
Nonavalent HPV vaccine to prevent recurrent anal or vulvar high-grade squamous intraepithelial lesions (VIVA trial): A randomized, double-blind, placebo-controlled trial.
(2026 Jun 1)
Int J Cancer 158(11): 2983-2994
Stankiewicz Karita HC, Magaret AS, Doody DR, Schouten JT, Mao C, Huh WK, Grieco VS, Seymour MA, Varon D, Shrader KH, Xi LF, Galloway DA, Wald A, Madeleine MM
Show complete publication list